Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorYılmaz, Gülçin
dc.contributor.authorÇoban, Hikmet
dc.contributor.authorSarıoğlu, Nurhan
dc.contributor.authorErel, Fuat
dc.contributor.authorYılmaz, Merve Akış
dc.contributor.authorÇolak, Mustafa
dc.contributor.authorŞenel, Merve Yumrukuz
dc.contributor.authorHişmioğulları, Adnan Adil
dc.date.accessioned2024-12-20T12:57:43Z
dc.date.available2024-12-20T12:57:43Z
dc.date.issued2024en_US
dc.identifier.issn2077-0383
dc.identifier.urihttps://doi.org/10.3390/jcm13226823
dc.identifier.urihttps://hdl.handle.net/20.500.12462/15612
dc.description.abstractHepcidin is a biomarker produced by hepatocytes in chronic disease anemia and is known to increase during chronic inflammation. This study compares the hepcidin levels in idiopathic pulmonary fibrosis (IPF) patients and controls, evaluating its relationship with anemia and systemic inflammation in IPF patients. Methods: This study included 82 IPF patients and 31 controls. Hepcidin levels were compared between the two groups. In the IPF group, the hepcidin and anemia parameters were compared between anemic and non-anemic patients. The significance between the hepcidin and systemic inflammation parameters such as Erythrocyte Sedimentation Rate, CRP (C-reactive protein) levels, ferritin levels, and the Systemic Immune–Inflammation Index (SII) was investigated. Erythrocyte Sedimentation Rate, C-reactive protein (CRP) levels, and ferritin levels were measured using automated analyzers. Hepcidin and erythropoietin (EPO) levels were determined using ELISA kits. Results: A significant difference in hepcidin levels was found between the IPF and control groups (37.13 ± 14.92 vs. 25.77 ± 11.25, p < 0.001). No significant difference in hepcidin levels was found between anemic and non-anemic IPF patients (38.25 ± 16.2 vs. 36.7 ± 14.6, p = 0.719). No significant correlation was found between hepcidin levels and anemia parameters (serum iron, ferritin, vitamin B12, serum transferrin, transferrin saturation, total iron-binding capacity, hemoglobin, folate, and erythropoietin) in IPF patients. Despite significant differences in the systemic inflammation parameters (ferritin and CRP) between patients and controls, no significant correlation was found between their hepcidin and systemic inflammation parameters. Conclusions: Our study demonstrates that the hepcidin levels in IPF patients are elevated independently of anemia and systemic inflammation. We propose that hepcidin could be a potential biomarker to be investigated in IPF patients.en_US
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.relation.isversionof10.3390/jcm13226823en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHepcidinen_US
dc.subjectIdiopathic Pulmonary Fibrosisen_US
dc.subjectAnemiaen_US
dc.subjectInflammationen_US
dc.subjectBiomarkeren_US
dc.subjectErythropoietinen_US
dc.subjectFerritinen_US
dc.subjectSystemic Immune–Inflammation Indexen_US
dc.titleCould hepcidin be a new biomarker in patients with idiopathic pulmonary fibrosis (IPF)?en_US
dc.typearticleen_US
dc.relation.journalJournal of Clinical Medicineen_US
dc.contributor.departmentTıp Fakültesien_US
dc.contributor.authorID0009-0004-3487-7721en_US
dc.contributor.authorID0000-0001-6730-9932en_US
dc.contributor.authorID0000-0002-5180-9649en_US
dc.contributor.authorID0000-0002-5050-5694en_US
dc.contributor.authorID:0000-0002-5338-7355en_US
dc.contributor.authorID0000-0002-8458-3535en_US
dc.contributor.authorID0000-0003-0205-5075en_US
dc.contributor.authorID0000-0001-9982-2714en_US
dc.identifier.volume13en_US
dc.identifier.issue12en_US
dc.identifier.startpage1en_US
dc.identifier.endpage13en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster